Patents by Inventor Klaus Edvardsen
Klaus Edvardsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9540450Abstract: The invention relates to novel methods for the treatment of tumors, comprising administration of a bispecific antibody or a combination of two or more non-cross-blocking antibodies that recognize the same target antigen or antigenic complex. In particular, the invention relates to a method for inducing complement-mediated cell killing in the treatment of a tumor, said method comprising combined administration, to a human being in need thereof, of a first antibody and a second antibody, wherein said first antibody binds EGFR, said second antibody binds EGFR, said first and second antibody are non-cross-blocking, and the dosage regimen is such that CDC is obtained at the tumor site.Type: GrantFiled: March 6, 2014Date of Patent: January 10, 2017Assignee: GENMAB A/SInventors: Jan Van De Winkel, Paul Parren, Willem Karel Bleeker, Klaus Edvardsen, Jeroen Lammerts Van Bueren, Thomas Valerius, Michael Dechant, Wencke Weisner, Sven Berger
-
Patent number: 9428582Abstract: The invention relates to a method for the treatment of a disease susceptible to anti-EGFR treatment, comprising the step of administering, to a human being in nee thereof, a combination of an anti-EGFR agent and an anti-neutrophil-chemoattracta agent, wherein said anti-neutrophil-chemoattractant agent is administered in a dosage regimen that is sufficient to reduce one or more undesired dermatological side-effects the anti-EGFR agent. In one embodiment, the anti-EGFR agent is an anti-EGF antibody and the anti-neutrophil-chemoattractant agent is an anti-IL-8 antibody.Type: GrantFiled: July 3, 2007Date of Patent: August 30, 2016Assignee: GENMAB A/SInventors: Klaus Edvardsen, Steen Lisby, Ole Baadsgaard
-
Publication number: 20140348833Abstract: The invention relates to novel methods for the treatment of tumors, comprising administration of a bispecific antibody or a combination of two or more non-cross-blocking antibodies that recognize the same target antigen or antigenic complex. In particular, the invention relates to a method for inducing complement-mediated cell killing in the treatment of a tumor, said method comprising combined administration, to a human being in need thereof, of a first antibody and a second antibody, wherein said first antibody binds EGFR, said second antibody binds EGFR, said first and second antibody are non-cross-blocking, and the dosage regimen is such that CDC is obtained at the tumor site.Type: ApplicationFiled: March 6, 2014Publication date: November 27, 2014Applicant: GENMAB A/SInventors: Jan VAN DE WINKEL, Paul PARREN, Willem Karel BLEEKER, Klaus EDVARDSEN, Jeroen Lammerts VAN BUEREN, Thomas VALERIUS, Michael DECHANT, Wencke WEISNER, Sven BERGER
-
Patent number: 8198302Abstract: Novel quinone and catechol compositions, compositions containing prodrugs of quinone and catechol compositions, and methods of use for the treatment of solid tumor cancers and other vascular proliferative disorders. The disclosure particularly relates to the discovery of dual activity agents capable of generating both a vascular targeting effect and direct tumor cell cytotoxicity in order to achieve an enhanced anti-tumor response in a patient.Type: GrantFiled: March 1, 2004Date of Patent: June 12, 2012Assignees: OXiGENE, Inc., Baylor UniversityInventors: David J. Chaplin, Klaus Edvardsen, Kevin G. Pinney, Joseph Anthony Prezioso, Mark Wood
-
Publication number: 20110256142Abstract: The invention relates to novel methods for the treatment of tumors, comprising administration of a bispecific antibody or a combination of two or more non-cross-blocking antibodies that recognize the same target antigen or antigenic complex. In particular, the invention relates to a method for inducing complement-mediated cell killing in the treatment of a tumor, said method comprising combined administration, to a human being in need thereof, of a first antibody and a second antibody, wherein—said first antibody binds EGFR, —said second antibody binds EGFR, —said first and second antibody are non-cross-blocking, and—the dosage regimen is such that CDC is obtained at the tumor site.Type: ApplicationFiled: September 5, 2008Publication date: October 20, 2011Applicant: GENMAB A/SInventors: Jan Van De Winkel, Paul Parren, Willem Karel Bleeker, Klaus Edvardsen, Jeroen Lammerts Van Bueren, Thomas Valerius, Michael Dechant, Wencke Weisner, Sven Berger
-
Publication number: 20100150936Abstract: The invention relates to a method for the treatment of a disease susceptible to anti-EGFR treatment, comprising the step of administering, to a human being in nee thereof, a combination of an anti-EGFR agent and an anti-neutrophil-chemoattracta agent, wherein said anti-neutrophil-chemoattractant agent is administered in a dosage regimen that is sufficient to reduce one or more undesired dermatological side-effects the anti-EGFR agent. In one embodiment, the anti-EGFR agent is an anti-EGF antibody and the anti-neutrophil-chemoattractant agent is an anti-IL-8 antibody.Type: ApplicationFiled: July 3, 2007Publication date: June 17, 2010Applicant: GENMAB A/SInventors: Klaus Edvardsen, Steen Lisby, Ole Baadsgaard
-
Publication number: 20090258937Abstract: Methods and pharmaceutical compositions for modulating tumor growth or metastasis are provided.Type: ApplicationFiled: November 7, 2008Publication date: October 15, 2009Inventors: Francis Y. Lee, Ronald Peck, David Chaplin, Ronald Pero, Klaus Edvardsen
-
Patent number: 7456214Abstract: Chrome compounds have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds as well as related derivatives are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting chemotherapeutic agents or to have vascular targeting activity resulting in the selective prevention and/or destruction of nonmalignant proliferating vasculature.Type: GrantFiled: May 21, 2004Date of Patent: November 25, 2008Assignees: Baylor University, OXiGENE, Inc.Inventors: Kevin G. Pinney, Phyllis Arthasary, Anupama Shirali, Klaus Edvardsen, David J. Chaplin
-
Patent number: 7384925Abstract: Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.Type: GrantFiled: July 18, 2005Date of Patent: June 10, 2008Assignees: OXiGENE, Inc., Baylor UniversityInventors: David J. Chaplin, Charles Manly Garner, III, Robert Ronald Kane, Kevin G. Pinney, Joseph Anthony Prezioso, Klaus Edvardsen
-
Patent number: 7091240Abstract: A diverse set of tubulin binding agents have been discovered which are structurally characterized, in a general sense, by a semi-rigid molecular framework capable of maintaining aryl-aryl, pseudo pi stacking distances appropriate for molecular recognition of tubulin. In phenolic or amino form, these ligands may be further functionalized to prepare phosphate esters, phosphate salts, phosphoramidates, and other prodrugs capable of demonstrating selective targeting and destruction of tumor cell vasculature.Type: GrantFiled: April 29, 2003Date of Patent: August 15, 2006Assignees: Oxigene, Inc., Baylor UniversityInventors: Kevin G. Pinney, Vani P. Mocharla, Zhi Chen, Charles M. Garner, Mallinath Hadimani, Raymond Kessler, James M. Dorsey, Klaus Edvardsen, David J. Chaplin, Joseph Prezioso, Usha Ghatak, legal representative, Anjan Ghatak, deceased
-
Patent number: 7001926Abstract: A diverse set of tubulin binding agents have been discovered which are structurally characterized, in a general sense, by a semi-rigid molecular framework capable of maintaining aryl-aryl, pseudo pi stacking distances appropriate for molecular recognition of tubulin. In phenolic or amino form, these ligands may be further functionalized to prepare phosphate esters, phosphate salts, phosphoramidates, and other prodrugs capable of demonstrating selective targeting and destruction of tumor cell vasculature.Type: GrantFiled: April 1, 2003Date of Patent: February 21, 2006Assignees: Oxigene, Inc., Baylor UniversityInventors: Kevin G. Pinney, Vani P. Mocharla, Zhi Chen, Usha R. Ghatak, legal representative, Mallinath Hadimani, Jimmy Kessler, James M. Dorsey, Klaus Edvardsen, David J. Chaplin, Joseph Prezioso, Anjan Ghatak, deceased
-
Publication number: 20060035868Abstract: Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.Type: ApplicationFiled: July 18, 2005Publication date: February 16, 2006Inventors: David Chaplin, Charles Garner, Robert Kane, Kevin Pinney, Joseph Prezioso, Klaus Edvardsen
-
Publication number: 20050245490Abstract: Trimethoxyphenyl substituted indole ligands have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds as well as related derivatives are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting chemotherapeutic agents or to have vascular targeting activity resulting in the selective prevention and/or destruction of nonmalignant proliferating vasculature.Type: ApplicationFiled: May 21, 2004Publication date: November 3, 2005Inventors: Kevin Pinney, Phyllis Arthasary, Anupama Shirali, Klaus Edvardsen, David Chaplin
-
Publication number: 20050245489Abstract: Trimethoxyphenyl substituted indole ligands have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds as well as related derivatives are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting chemotherapeutic agents or to have vascular targeting activity resulting in the selective prevention and/or destruction of nonmalignant proliferating vasculature.Type: ApplicationFiled: May 3, 2004Publication date: November 3, 2005Inventors: Kevin Pinney, Phyllis Arthasary, Anupama Shirali, Klaus Edvardsen, David Chaplin
-
Publication number: 20050209310Abstract: Methods and pharmaceutical compositions for modulating tumor growth or metastasis and methods for prognosing treatment therewith are provided.Type: ApplicationFiled: December 22, 2004Publication date: September 22, 2005Inventors: David Chaplin, Klaus Edvardsen, Scott Young
-
Patent number: 6919324Abstract: Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.Type: GrantFiled: October 28, 2002Date of Patent: July 19, 2005Assignees: Oxigene, Inc., Baylor UniversityInventors: David J. Chaplin, Charles Manly Garner, III, Robert Ronald Kane, Kevin G. Pinney, Joseph Anthony Prezioso, Klaus Edvardsen
-
Publication number: 20040242696Abstract: Novel quinone and catechol compositions, compositions containing prodrugs of quinone and catechol compositions, and methods of use for the treatment of solid tumor cancers and other vascular proliferative disorders. The disclosure particularly relates to the discovery of dual activity agents capable of generating both a vascular targeting effect and direct tumor cell cytotoxicity in order to achieve an enhanced anti-tumor response in a patient.Type: ApplicationFiled: March 1, 2004Publication date: December 2, 2004Inventors: David J. Chaplin, Klaus Edvardsen, Kevin G. Pinney, Joseph Anthony Prezioso, Mark Wood
-
Patent number: 6773702Abstract: A method of treating immune suppression in a warm-blooded animal bearing a tumor, by administering to the animal an amount of combretastatin A4 and/or a prodrug thereof effective to enhance immune responsiveness without causing vascular destruction. Immunotherapy treatment to inhibit or kill tumor cells includes administering to the animal an immune-response-stimulating agent such as a vaccine of tumor cells genetically modified to produce an immune-response-enhancing cytokine while counteracting tumor-induced immune suppression in the animal by administering combretastatin A4 and/or a prodrug thereof.Type: GrantFiled: December 26, 2001Date of Patent: August 10, 2004Assignees: OXiGENE, Inc., Bristol-Myers Squibb CompanyInventors: Ronald W. Pero, Francis Y. F. Lee, Klaus Edvardsen, Hans Olov Sjögren
-
Patent number: RE45720Abstract: Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.Type: GrantFiled: February 13, 2014Date of Patent: October 6, 2015Assignees: OXiGENE, Inc., Baylor UniversityInventors: David J. Chaplin, Charles Manly Garner, III, Robert Ronald Kane, Kevin G. Pinney, Joseph Anthony Prezioso, Klaus Edvardsen
-
Patent number: RE45907Abstract: Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.Type: GrantFiled: February 13, 2014Date of Patent: March 1, 2016Assignees: OXiGENE, Inc., Baylor UniverswityInventors: David J. Chaplin, Charles Manly Garner, III, Robert Ronald Kane, Kevin G. Pinney, Joseph Anthony Prezioso, Klaus Edvardsen